ABOUT US
Aniesis is a drug discovery and development biotech, led by a team with 80+ years of combined life sciences experience. Having created value for its partners, collaborators and patients by advancing multiple preclinical projects into the clinic, Aniesis is committed to provide innovative therapeutics to those who need it the most.
- Aniesis through its collaborations like Aayam, has access to global technologies and capabilities across the drug discovery & development spectrum
- Scalable preclinical R&D capabilities under a single roof, with service experience and potential for new collaborations
COLLABORATIVE DRUG DISCOVERY
Aniesis is committed to bringing innovative therapies to patients, leveraging our expertise and experience through:
GLOBAL PARTNERSHIP AND ALLIANCES
- Working with global partners to discover and advance preclinical R&D assets for improved patient outcomes.
- Embedded relationships with different collaborative models, tailored for each project and partner.
PLATFORM TECHNOLOGIES ACROSS DIVERSE THERAPEUTIC AREAS
- Proprietary platform technologies to accelerate, enable and repurpose drugs and novel therapeutics.
- Therapeutic area expertise spanning oncology, metabolic disorders, CNS, mitochondrial dysfunction and rare genetic disorders.
FOCUS ON RARE AND NEGLECTED DISEASES
- Integrated infrastructure, with therapeutic agnostic experience and the agility of a small biotech makes Aniesis ideally suited to tackle rare and neglected diseases.
- Using repurposing to create a viable strategy for addressing rare diseases.
INTEGRATED DRUG DISCOVERY SERVICES
CHEMISTRY
- NCE design and synthesis, Hit-to-lead and lead optimization.
- Library design and synthesis - various scaffolds like heterocycles, steroids, PROTAC, etc supported by complete Analytical capabilities.
IN-VITRO PHARMACOLOGY
- Assay development for enzymatic and cell- based screening.
- Biomarker validation & profiling
- IN-VITRO ADME Profiling studies
IN-VIVO PHARMACOLOGY
- Range of in VIVO pre-clinical efficacy, pharmacology, and safety models across diverse therapeutic applications
- Development of complex, disease specific IN-VIVO models
- Pharmacokinetic Studies in rodents
TEAM
Dr. Mena Mirhom Garcia
Director & CEODr. Mena has been in drug discovery and development for more than 15 years. An MBA in Finance, he is responsible for advancing Aniesis’s global collaboration and business structuring, and oversees corporate finance, business development, and commercialization strategy.
Steven Marong
Director & Head OperationsSteven has over 20 years of experience, combined over IT industry and life sciences space. An IT post-graduate, he manages key components of facility & operations, intellectual property, data and information management, and project management.
Annabel Hodgson, PhD
Director & Head R&DAnnabel has over 26 years of experience in research and development. A PhD in organic chemistry, her experience has been largely across genomics, proteomics, pharmacology and preclinical development of NCE programs.
Robbie Peters, PhD
Head Medicinal ChemistryRobbie has more than 20 years’ experience in research and development. A PhD in chemistry, he has worked extensively with novel and established targets in different therapeutic areas like oncology, metabolic disorders and immunology.
Jonathan Clenton
FinanceJonathan has over 24 years of experience in finance and accounts. A post graduate in finance, he specializes in taxation, management information system and statutory compliances.
Sandra Shireen
Medicinal ChemistrySandra has been in the drug discovery space for approximately 24 years. An MSc in organic chemistry, he specializes in synthetic chemistry, medicinal chemistry and drug modification.
Siddhar Selvan,PhD
Analytical ChemistrySiddhar has over 11 years of experience in drug development. A PhD in Botany, he specializes in pharmacokinetic studies in LCMS/MS.
